RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock
Session close: $3.61. Regular-session share volume: 24,809,555. Change from previous close: +4.18%.
Key developments
Ahead of the session, reporting highlighted Sanofi exercising its option on the collaboration’s first immunology candidate, triggering a milestone payment and advancing the program into initial clinical testing. Positive trial updates in familial adenomatous polyposis and endometrial cancer also supported progress across Recursion’s partnered and internal pipeline.
Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone · Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone
Separate coverage flagged dilution considerations following a completed equity offering and questioned whether current sales supported Recursion’s valuation. These financing and valuation concerns remain distinct from the reported clinical progress.
Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales? · Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone
A poster on X expressed a strongly bearish view and claimed a decline, but that unverified account differs from the recorded session gain. The news reports all predate the session and concern earlier developments; neither they nor the limited X sample establish what caused the session’s move.
Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone · Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions · Source post by @ZeroNoiseReport
News sources
Company news Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target · Company news Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales? · Company news Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone · Company news Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone? · Company news Recursion Pharmaceuticals (RXRX) Stock Sees Modest Fair Value Lift After Analyst Target Revisions · Company news Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone